Climb Bio provides updates on the progress of their budoprutug and CLYM116 programs, with key milestones anticipated in 2026.
First patients have been dosed in various Phase trials, including pMN, ITP, SLE, and healthy volunteer studies.
The company achieved regulatory clearance for SLE IND in China and is expecting data-rich outcomes in 2026.
Pipeline Progress
Initiation of Phase 2 trial in pMN, ongoing trials in ITP and SLE, and successful SC formulation Phase 1 trial.
Financial Position
Strong financial position with cash runway expected into 2028.
Strategic Priorities for 2026
Focused on advancing budoprutug and CLYM116 programs while addressing unmet needs in immune-mediated diseases.
- 2026 is expected to be transformative for Climb Bio with data from ongoing trials shaping future treatment strategies.
- The company's progress in clinical trials indicates a promising outlook for addressing immune-mediated diseases.
Climb Bio is poised for a data-rich year in 2026 with promising developments in their pipeline programs. The company's strategic priorities and strong financial position set the stage for continued growth and innovation in the field of biotechnology.